BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 20450911)

  • 1. Zonisamide: aspects in neuroprotection.
    Rösler TW; Arias-Carrión O; Höglinger GU
    Exp Neurol; 2010 Aug; 224(2):336-9. PubMed ID: 20450911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zonisamide suppresses endoplasmic reticulum stress-induced neuronal cell damage in vitro and in vivo.
    Tsujii S; Ishisaka M; Shimazawa M; Hashizume T; Hara H
    Eur J Pharmacol; 2015 Jan; 746():301-7. PubMed ID: 25261037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zonisamide: a new drug for Parkinson's disease.
    Murata M
    Drugs Today (Barc); 2010 Apr; 46(4):251-8. PubMed ID: 20502722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease.
    Murata M
    Curr Pharm Des; 2004; 10(6):687-93. PubMed ID: 14965331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective effects of zonisamide target astrocyte.
    Asanuma M; Miyazaki I; Diaz-Corrales FJ; Kimoto N; Kikkawa Y; Takeshima M; Miyoshi K; Murata M
    Ann Neurol; 2010 Feb; 67(2):239-49. PubMed ID: 20225289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zonisamide has beneficial effects on Parkinson's disease patients.
    Murata M; Horiuchi E; Kanazawa I
    Neurosci Res; 2001 Dec; 41(4):397-9. PubMed ID: 11755227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiepileptic drugs and neuroprotection: current status and future roles.
    Willmore LJ
    Epilepsy Behav; 2005 Dec; 7 Suppl 3():S25-8. PubMed ID: 16239127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases].
    Janszky J
    Ideggyogy Sz; 2009 Nov; 62(11-12):383-9. PubMed ID: 20025128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical aspects of neuroprotection in Parkinson's disease.
    Przuntek H
    J Neural Transm Suppl; 1994; 43():163-9. PubMed ID: 7884398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease.
    Sano H; Murata M; Nambu A
    J Neurochem; 2015 Jul; 134(2):371-81. PubMed ID: 25857446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease.
    Grover ND; Limaye RP; Gokhale DV; Patil TR
    Indian J Pharmacol; 2013; 45(6):547-55. PubMed ID: 24347760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiparkinsonian drugs and their neuroprotective effects.
    Kitamura Y; Kakimura J; Taniguchi T
    Biol Pharm Bull; 2002 Mar; 25(3):284-90. PubMed ID: 11913520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mechanistic approach to explore the neuroprotective potential of zonisamide in seizures.
    Kumar B; Medhi B; Modi M; Saikia B; Attri SV; Patial A
    Inflammopharmacology; 2018 Aug; 26(4):1125-1131. PubMed ID: 29644555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatments in the early stage of Parkinson disease].
    Rascol O
    Rev Neurol (Paris); 2008 Apr; 164 Spec No 2():F77-84. PubMed ID: 18680822
    [No Abstract]   [Full Text] [Related]  

  • 15. Neuropharmacology of zonisamide, a new antiepileptic drug.
    Hammond EJ; Perchalski RJ; Wilder BJ; McLean JR
    Gen Pharmacol; 1987; 18(3):303-7. PubMed ID: 3552863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of zonisamide (CI-912) on a synaptic system model.
    Fromm GH; Shibuya T; Terrence CF
    Epilepsia; 1987; 28(6):673-9. PubMed ID: 3691417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rifampicin and Parkinson's disease.
    Bi W; Zhu L; Jing X; Liang Y; Tao E
    Neurol Sci; 2013 Feb; 34(2):137-41. PubMed ID: 22821065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological therapy in Parkinson's disease: focus on neuroprotection.
    Kincses ZT; Vecsei L
    CNS Neurosci Ther; 2011 Oct; 17(5):345-67. PubMed ID: 20438581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole.
    Albrecht S; Buerger E
    Curr Med Res Opin; 2009 Dec; 25(12):2977-87. PubMed ID: 19842998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology and mechanism of action of zonisamide.
    Biton V
    Clin Neuropharmacol; 2007; 30(4):230-40. PubMed ID: 17762320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.